Medicaid GLP-1 Coverage Through 2031: What the BALANCE Model Means for You
Author
glp winnerDate Published
- Twitter
- Facebook
- LinkedIn
- Instagram
- Copy Link
If you have Medicaid and a GLP-1 medication has felt out of reach, we have great news for you. A new federal program called the BALANCE Model is opening the door to Medicaid coverage of GLP-1s like Wegovy and Zepbound through December 2031 (CMS). State Medicaid agencies started signing up in May 2026, and the price terms with the drugmakers have already been negotiated, so what happens in your state over the next year is the part that matters most for you (KFF).
Who This Helps
This is for you if you have Medicaid and have been told a GLP-1 is not covered. It is also for you if you live in a state where weight management coverage has been limited, you are helping a parent or partner navigate Medicaid prescription benefits, or you are already on a GLP-1 and want to know how the rules in your state may shift.
Does This Affect You Today?
Probably not yet. The program officially started in May 2026, but each state has to decide whether to participate, and the application deadline for state Medicaid agencies is July 31, 2026 (KFF). Until your state signs on and your state plan goes live, your current Medicaid rules for GLP-1 medications stay the same.
The fastest way to find out where you stand is to call the number on the back of your Medicaid card. They should be able to confirm whether your state has joined the BALANCE Model, what your current GLP-1 coverage looks like, what prior authorization steps you would need, and what your copay would be if your state opts in.
How the BALANCE Model Actually Works
BALANCE is short for Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth. The name is a mouthful, but the idea is straightforward: get GLP-1 medications and lifestyle support to more people on Medicare and Medicaid who live with obesity (CMS).
Two Different Numbers, and Why They Both Matter
There are two prices in the BALANCE Model that often get mixed up. These work together to help expand coverage, but they work differently depending on which plan you’re on.
The first is the $245 net price. That is the amount the federal government and participating Medicare Part D plans pay per 30-day supply for the GLP-1 medications included in the model, after rebates. The Centers for Medicare and Medicaid Services negotiated that figure directly with Novo Nordisk and Eli Lilly. Medicare plan members will not see $245 on their pharmacy receipt. It is the program-side wholesale figure (KFF).
The second is what a Medicare member actually pays at the counter, also called their copay or out-of-pocket cost. Under the Medicare GLP-1 Bridge, eligible Medicare Part D enrollees pay a $50 copay per month for Wegovy or Zepbound (KFF). On the Medicaid side of BALANCE, the discounted net price the state pays is also negotiated but is kept private through supplemental rebate agreements (KFF). What a Medicaid member pays out of pocket on Medicaid depends on the state's copay rules, which under federal law are capped at small amounts.
What This Means If You Are on Medicaid for Diabetes
Federal law already requires state Medicaid programs to cover GLP-1 medications for FDA-approved indications other than obesity, including type 2 diabetes, under the Medicaid Drug Rebate Program (KFF). What is not federally standardized is the experience. Which specific GLP-1 product is on your state's preferred drug list, what prior authorization steps you need, and what step therapy your plan requires before approving the medication all vary state by state.
The BALANCE Model does not change the federal requirement to cover GLP-1s for diabetes. It does add a new pricing structure that may expand which specific GLP-1 products your state offers, and that could matter for you if you have struggled to get the particular GLP-1 your clinician recommends.
Who Qualifies for Weight Management Coverage If Your State Joins
Eligibility under the BALANCE Model for weight management coverage follows clinical criteria similar to the Medicare GLP-1 Bridge. There are two paths in: a body mass index of 35 or higher on its own, or a BMI of 27 or higher along with another condition like type 2 diabetes, high blood pressure, sleep apnea, or established cardiovascular disease (KFF). States can offer broader coverage than the model requires, but they cannot make the criteria stricter.
What the Model Pairs With Medication
The name BALANCE is doing real work in policy design. The model is not just about a prescription. It also pairs participants with lifestyle support programs provided at no cost by the drugmakers, meant to help with healthy eating, physical activity, and sticking with the medication (KFF). The programs are available online or offline for people with limited digital access. Specific details on what each program looks like are still being released.
How This Connects to the Medicare GLP-1 Bridge
These two programs are easy to mix up, and the timeline has changed once already, so it helps to walk through what was originally planned and what has shifted.
Originally, the plan had two pieces working together. The Medicare GLP-1 Bridge was a short program designed to run from July through December 2026, giving eligible Medicare Part D enrollees access to GLP-1s for obesity at a $50 copay. The Bridge was meant to hand off to the Medicare side of the BALANCE Model on January 1, 2027 (KFF).
That changed on April 21, 2026. CMS announced that the Medicare side of the BALANCE Model would not launch in 2027 after all, and extended the Medicare GLP-1 Bridge through the end of 2027 to fill the gap (KFF Quick Takes). So if you are on Medicare, the Bridge is still your path to GLP-1 coverage for obesity for the next year and a half.
The Medicaid side of BALANCE is on a different schedule, and it is still on track. It started in May 2026 and runs through December 2031.
If you are dual-eligible, meaning you have both Medicare and Medicaid, how your coverage works depends on which plan is paying for the prescription. Your local State Health Insurance Assistance Program (SHIP) is a free resource that should be able to explain how Medicare and Medicaid interact in your specific situation, including how the BALANCE Model and the Medicare GLP-1 Bridge might affect your prescription costs.
What Could Still Change
This is a new federal model, with all the moving parts prone to change. State Medicaid agencies are still applying, and not every state will join (KFF). The list of GLP-1 medications included in the model could grow over time, especially as newly approved options like Foundayo, the once-daily oral GLP-1 that the FDA approved on April 1, 2026, get folded in. And as the Medicare side already showed, timelines can shift.
The steady move right now is to track whether your state has joined, learn the eligibility criteria, and ask your clinician to start documenting your case if your state opts in. Medicaid prescription decisions go through preferred drug lists and prior authorization, and that paperwork moves faster when your clinician has it ready ahead of time.
Final Takeaway
If you have Medicaid and you have been waiting on coverage for a GLP-1 medication, the BALANCE Model is the most concrete federal effort to expand access through December 2031. It is voluntary for states, the prices have been negotiated, and the program pairs the medication with nutrition and lifestyle support.
Your next step depends on your state. The most reliable place to check is your state Medicaid agency. And if your state has not applied yet, that does not mean coverage is off the table. The decisions are still being made, and your clinician's documentation of medical necessity stays useful no matter which path your state chooses.
If you enjoy posts like these, you can subscribe to receive newsletter updates.
Sources
Keep Reading
Lilly wants retatrutide classified as a biologic, but the FDA is not agreeing, now there is a lawsuit. What the lawsuit and OFA brief actually say.
A new mouse study suggests pausing a GLP-1 makes restarts less effective. Here is how strong the evidence is and what to think about before a break.
Starting July 1, 2026, Medicare Part D patients could get GLP-1s for $50/month. Here's who qualifies, what's covered, and what's still in motion.
Categories
Curated by
